Influenza A virus vaccines and inhibitors

The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for...

Full description

Bibliographic Details
Main Authors: Arnold, Edward C., Krug, Robert M., Twu, Karen Y., Montelione, Gaetano T., Das, Kalyan Kumar, Ma, Li-Chung, Xiao, Rong, Rei-Lin Kuo
Format: Article in Journal/Newspaper
Language:unknown
Published: United States Patent and Trademark Office 2010
Subjects:
A61B50/39
A61K38/162
A61K39/145
A61K2039/5254
A61K2039/53
C07K14/005
C07K14/47
C12N7/00
C12N2760/16034
C12N2760/16071
C12N2760/16122
C12N2760/16134
C12N2760/16162
435/5
Avian flu
Online Access:https://dx.doi.org/10.26153/tsw/4111
https://repositories.lib.utexas.edu/handle/2152/77022
Description
Summary:The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Similar Items